U.S. markets closed

Vapotherm, Inc. (VAPO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
27.49-0.14 (-0.51%)
At close: 4:00PM EDT
27.49 +0.06 (0.22%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close27.63
Bid27.66 x 800
Ask28.00 x 1100
Day's Range27.43 - 28.20
52 Week Range16.64 - 38.46
Avg. Volume192,034
Market Cap714.93M
Beta (5Y Monthly)-1.59
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vapotherm, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/18/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Business Wire

    Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity

    EXETER, N.H., September 08, 2021--Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addition of assembly lines in Mexico which will increase capacity by 75% without adding material fixed costs and prepare the Company for the possibility that COVID-19 becomes a permanent part of the respiratory landsc

  • Business Wire

    Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

    EXETER, N.H., August 30, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is designed to provide high velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source. It is estimated that 50% of U.S. hospital beds don’t have wall air. When paired with an oxygen source, the HVT 2.0 will support patien

  • Business Wire

    Vapotherm Reports Second Quarter 2021 Financial Results

    EXETER, N.H., August 09, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2021 financial results.